strides receives usfda approval for prednisone tablets-Read all the latest news headlines & breaking news on strides receives usfda approval for prednisone tablets in Hindi on haribhoomi.com
Strides Pharma to pursue portfolio maximisation in regulated markets
February 10, 2021
R Ananthanarayanan, Managing Director & CEO, Strides Pharma Sciences×
To develop products across multiple therapeutics segments
Strides Pharma Science Limited plans to pursue portfolio maximisation strategy across the regulated markets to unlock value. It is also exploring to develop a wide range of products across multiple therapeutics segments.
“Further to the Stelis demerger, Strides will keep open the option of adding injectables to its portfolio to complement its oral solid and topicals business as part of the portfolio maximisation strategy and will retain 100 per cent of the economics for the business,” the company’s spokesperson told
Search jobs 04-Feb-2021 Global Anti-Rickettsial Treatment Market Seeking Excellent Growth |Industry Share, Size 2021 Movements by Growth Status, Trend Analysis
Data Bridge Market Research has recently added a concise research on the
Global Anti-Rickettsial Treatment Market to depict valuable insights related to significant market trends driving the industry. The
Global Anti-Rickettsial Treatment Market report makes available the basic information about industry, definition, classification, application, industry chain structure, industry overview and international market analysis. As per this report, the market is expected to grow at a substantial Compound Annual Growth Rate (CAGR) during the forecast period 2020-2027. This market document provide the market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, and market demand and supply scenarios. It also gives wid
Strides Board approves demerger of its Biotech business under Stelis Biopharma
Bengaluru, Feb 4 (UNI) Strides Pharma Science Limited (Strides), Bengaluru headquartered global Pharmaceutical Company on Thursday announced that its Board of Directors have approved in principle the demerger of its biotech business under Stelis Biopharma (Stelis).
The demerger is expected to unlock significant value for Strides shareholders.
A Committee will be formed to explore various options of value discovery including listing of the business on a standalone basis and recommend to the Audit Committee, Committee of Independent Directors and Board including the Scheme, swap ratio and way forward, according to a release here on Thursday.
Aditya Puri to Chair the Board of Stelis Biopharma, the proposed demerged Biotech Business of Strides
Posted On: 2021-02-04 01:37:49 (Time Zone: Arizona, USA)
Strides Pharma Science Limited (Strides) today announced that the Board of Directors of the Company have approved in principle the demerger of its biotech business under Stelis Biopharma (Stelis). The demerger is expected to unlock significant value for Strides shareholders.
The Board will form a Committee of Directors to explore various options of value discovery including listing of the business on a standalone basis. The Committee will recommend the proposals to the Audit Committee, Committee of Independent Directors and Board including the Scheme, swap ratio and way forward.